A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

Happy New Year!

2013 was a productive second year for the WIPO Re:Search Partnership Hub; BVGH facilitated 31 new research Agreements and welcomed 16 new Members. Five hosting arrangements were also coordinated and executed in 2013. We are starting to see the impact of WIPO Re:Search as several of these research collaborations have identified screening hits, while other collaborations have improved the drug attributes of previously-identified lead candidates. As new partnerships develop and existing ones progress, we anticipate an even greater impact in 2014.

Last year ended on a busy note for BVGH - I attended the First Biennial Scientific Conference on Medicines Regulation in Africa and Roopa attended 2013 Technology Transfer Summit Asia meeting. Both meetings provided BVGH with opportunities to present WIPO Re:Search activities and achievements, as well as engage current and prospective Members.

I am pleased to welcome our newest Member, the University of New South Wales, to WIPO Re:Search.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent

President, BVGH
Special Announcement

BVGH will be releasing its next issue of the BVGH Funders Database, a comprehensive database of all open funding opportunities relevant to neglected disease research. This database summarizes and categorizes funding opportunities' critical information, including program description, disease and product focus, stage of R&D, researcher and institute eligibility requirements, geographic restrictions, deadline, contacts, and URL. The Database is updated quarterly and contains three tiers of funding opportunities:

Tier 1: grants that are often >$100,000 and have regular open call schedules
Tier 2: grants that may be <$100,000, lack complete information, or that do not have a regular schedule
Tier 3: travel awards, pre- and post-doctoral fellowships, conference awards

The opportunities' information is sortable to allow you to more easily identify relevant funding for which you are eligible.

If you would like to receive the Funders Database, please email Katy.

Cornerstones of Collaboration

Last month, Jennifer Dent presented the capacity-building hosting opportunities, which BVGH and WIPO arranged for WIPO Re:Search Member institutions, at the First Biennial Scientific Conference on Medicines Regulation in Africa in Johannesburg, South Africa. This conference presented an opportunity to engage scientists involved in drug development and regulatory initiatives in Africa. While at the event, Jennifer spoke with Peace Babalola, Dean, Faculty of Pharmacy, Director, Centre for Drug Discovery, Development, and
Production, University of Ibadan, and representatives from the World Bank, MSD*, and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

Jennifer presents the WIPO Re:Search capacity-building efforts
Roopa Ramamoorthi gave a presentation describing WIPO Re:Search and participated in two panels entitled, "Vaccines, biologicals, and public health - global challenges, emerging markets, and the opportunities for innovation, collaboration, and expansion" and "Outcome driven healthcare - key messages for TTOs and CEOs" at the 2013 Technology Transfer Summit (TTS) Asia meeting in Singapore last month. While in Singapore, Roopa also met with researchers from the Novartis Institute for Tropical Diseases (NITD), including Pei-Yong Shi, Executive Director/Senior Unit Head - Disease Biology, and Thierry Diagana, Head, NITD, as well as scientists from the National University of Singapore (NUS).

*Known as Merck in the US and Canada

**New Member Announcement**
This month, we are pleased to announce that the University of New South Wales has joined WIPO Re:Search.

Located in Sydney, Australia, the University of New South Wales is one of Australia’s leading research and teaching universities. The University’s School of Biotechnology and Biomolecular Sciences includes the department of Molecular Medicine, which combines fundamental biological and biomolecular sciences with applied biotechnology and medical focus. The department’s strengths include biomaterials and immunology. The School of Chemistry includes the department of Medicinal Chemistry, which seeks to design bioactive molecules, explore DNA-drug interactions, and understand natural product chemistry, among others.

**Partnership Hub Central**

Roopa and Katy Graef attended the 6th Annual CEND Symposium at UC Berkeley, which focused on academia and the global health pipeline. During the event, Roopa and Katy spoke with researchers from Anacor, PATH, UC Berkeley, UCSF, and the University of Buea. Fidelis Cho-Ngwa, Associate Professor of Biochemistry, University of Buea, spoke about his research, the state and complexities of drug discovery for onchocerciasis, as well as the achievements and capabilities of the University of Buea’s ANDI Centre of Excellence during the CEND symposium.
Fidelis Cho-Ngw a presents his research during the 6th Annual CEND Symposium

Katy coordinated a visit and meetings for Fidelis at Stanford University with Olfat Hammam, Professor of Pathology, Theodor Bilharz Research Institute (TBRI), and Michael Hsieh, Assistant Professor of Urology, Stanford University. BVGH arranged Olfat's sabbatical at Stanford with funding from the WIPO Australia Funds in Trust.
Member Spotlight

This month's Snapshot features Fidelis Cho-Ngw a from the University of Buea. Fidelis developed a medium-throughput system to screen compounds for microfilaricidal and macrofilaricidal activity against *Onchocerca* and *Loa loa* worms. His current interests include screens of traditional medicines as well as other natural products, and the development of a small animal model to examine the effects of *Onchocerca* macrofilaricides against *Loa loa* microfilariae.
Highlighted Contributions

Featured this month are three contributions submitted by the University of Buea to the WIPO Re:Search Database.

Onchocerciasis drug screening expertise and facilities  (ID: 2821)
The University of Buea is willing to enter into partnerships accessing its state-of-the-art facilities and expertise in drug screening for onchocerciasis, including whole-parasite and medium-throughput screens.

Access to biological materials and field testing for onchocerciasis  (ID: 2822)
The University of Buea has access to adult onchocerciasis patients, and can therefore provide partners with a range of biological materials, including serum and microfilarial parasites. The University can also undertake epidemiological surveys and field-testing.

Medicinal plants for onchocerciasis treatment  (ID: 2764)
The University of Buea has experience investigating crude plant extracts for selective activity in the search for novel filaricides.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

Global Health in the News

Recently, Luke Timmerman of Xconomy interviewed the president of the Bill & Melinda Gates Foundation Global Health Program, Trevor Mundel. In his interview, Trevor discussed the role of the pharmaceutical and biotechnology industry in global health, the differences in health technology requirements between the developed and developing world, and valuations of health interventions. While discussing his previous work developing the Coartem Dispersible, an anti-malarial formulated for children, Trevor mentioned, "...I saw what a small group can do to have a massive impact on a miniscule, shoestring budget..." Click here for the complete interview.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb. 2-7</td>
<td>Science of Malaria Eradication - Keystone Symposium</td>
<td>Merida, Mexico</td>
<td>Website</td>
</tr>
<tr>
<td>Feb. 17-20</td>
<td>4th Zing Drug Discovery Conference</td>
<td>Malaga, Spain</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event? Do you have a Research Request to highlight in the Snapshot? We want to hear from you! Please send feedback and suggestions via email.
WIPO Re:Search Founding Supporters

*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

The 2014 Winter Olympics are upon us and like the Games, which bring together the best and brightest athletes in the world, WIPO Re:Search convenes many of the globe’s most innovative and talented NTD, malaria, and tuberculosis researchers. Like the billions of Olympic spectators, WIPO and BVGH are cheering on our WIPO Re:Search Members.

Last month, two new WIPO Re:Search agreements were finalized. This brings the number of agreements to 46.

WIPO has completed and uploaded video interviews of two WIPO Re:Search Member researchers who participated in sabbatical opportunities at Novartis. These videos may be viewed on the WIPO Re:Search website and on YouTube.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Last month, the Eskitis Institute, Griffith University, in Australia, agreed to provide Swiss Tropical and Public Health Institute (Swiss TPH) with a selection of natural products to screen against soil-transmitted helminths and schistosomes.

Four researchers from WIPO Re:Search Member institutions participated in sabbatical opportunities at three WIPO Re:Search Members' locations last year. With financial support from the Japanese government, WIPO created video interviews of the researchers. The videos of Wellington Oyibo, Associate Professor, College of Medicine, University of Lagos, and Fidelis Chongwa, Associate Professor of Biochemistry, University of Buea, are available on the WIPO Re:Search website and on YouTube. Both Wellington and Fidelis participated in three-month sabbaticals at Novartis' site in Basel, Switzerland.
Member Announcement

This month, we regrettably inform you that AstraZeneca (AZ) will no longer be a Member of WIPO Re:Search.
Partnership Hub Central

While in Geneva last week, Jennifer Dent met with several Members and updated them on the status of WIPO Re:Search partnerships. Eduardo Pisani, Director General, and Andrew Jenner, Executive Director, Corporate Strategy and Legal Affairs, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), discussed the important impact that WIPO Re:Search is having on the advancement of R&D for neglected diseases. The IFPMA recently published a report, *Pharmaceutical R&D Projects to Develop New Cures for Patients with Neglected Conditions*, that describes IFPMA member participation in neglected disease R&D. WIPO Re:Search is highlighted on page 9 of the January 2014 report - "WIPO Re:Search: a collaborative platform to boost R&D". The report also lists several of the partnerships established through WIPO Re:Search.

WIPO Director General, Francis Gurry, met with Lila Feisee, Vice President, International Affairs, Biotechnology Industry Organization (BIO), and representatives from Abbvie, Johnson & Johnson, and Roche, to speak about his upcoming plenary session at the 2014 BIO International Convention in San Diego. During these discussions, Francis encouraged the companies to join WIPO Re:Search.

Tom Bombelles, Head, Global Health, WIPO, attended the WIPO Conference on Open Innovation: Collaborative Projects and the Future of Knowledge in Geneva, last month. Tom represented WIPO Re:Search on a panel session that included individuals from the Wellcome Trust, the World Health Organization (WHO), the Massachusetts Institute of Technology (MIT), and Médecins Sans Frontières (MSF). Additional conference attendees included numerous representatives from national governments.

Roopa Ramamoorthi and Katy Graef attended the Anthelmintics: From Discovery to Resistance meeting in San Francisco last week. The event provided the opportunity to interact with several Members, including Jennifer Keiser, Assistant Professor and Head of Helminth Drug Development Unit, Swiss TPH, John Rogers, Program Officer, Preclinical Parasite Drug Development, US National Institutes of Health (NIH), and Ronald Kaminsky, Head of Parasitology, Animal Health, Novartis, as well as engage potential new Members. During the conference, Roopa presented WIPO Re:Search and the agreements and collaborations involving helminth infections that BVGH has facilitated.
Highlighted Contributions

Featured this month are two contributions submitted by the University of Ibadan to the WIPO Re:Search Database.
Malaria and soil-transmitted helminth infection diagnostic evaluation services (ID: 2762)

The University’s Parasitology Unit has strong capacity for malaria and soil-transmitted helminthiases diagnostics evaluations, including hospital- and community-based evaluations. The unit is currently being equipped with facilities for molecular diagnosis of parasitic infection. Dr. Dada-Adegbola has had training both in immunology of parasitic infections and molecular diagnosis of parasitic infections, with an emphasis on malaria parasites and intestinal helminths. Some staff members have been trained to perform molecular diagnoses, and this knowledge is transferred, though training, to other staff.

Tuberculosis R&D services (ID: 2761)

The University of Ibadan has capacity for tuberculosis diagnostic evaluation, case management, and disease control. The University is involved in tuberculosis research and is currently building capacity to carry out clinical trials on tuberculosis diagnostics, drugs, and vaccines in accordance with international standards. The University is willing to partner with other organizations to strengthen tuberculosis R&D in order to reduce disease burden in its community.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

WIPO Re:Search in the News

WIPO published an article that not only highlights WIPO Re:Search and its successes to date, but also describes the human side of the diseases that the Consortium’s Members seek to combat. Click here to read the article.

Intellectual Property Watch published an article, “At WIPO, Global Experts Share Experiences On Open Collaboration,” describing the proceedings of the WIPO Conference on Open Innovation, which took place last month in Geneva. The article also discusses the connection between open innovation and intellectual property, and the role each play in confronting worldwide challenges, such as global health.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb. 17-20</td>
<td>4th Zing Drug Discovery Conference</td>
<td>Malaga, Spain</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 5-7</td>
<td>6th ASEAN Congress of Tropical Medicine and Parasitology</td>
<td>Kuala Lumpur, Malaysia</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event?  
Do you have a Research Request to highlight in the Snapshot?  
We want to hear from you! Please send feedback and suggestions via email.
WIPO Re:Search Pharmaceutical Members

*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

This email was sent to jdent@bvgh.org by jdent@bvgh.org |
Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
Dear WIPO Re:Search Members and Friends,

It has been a busy month for BVGH and WIPO Re:Search. With six new agreements finalized, the Consortium has surpassed its 50th collaboration.


Roopa, Katy, and I visited the University of British Columbia to meet with researchers from several of its impressive groups, including the Neglected Global Diseases Initiative. It was a great opportunity to see the University’s beautiful and growing campus and to learn about the innovative infectious disease research being performed there.

I am pleased to welcome our newest Member, Kineta®, to WIPO Re:Search.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
Special Announcement

The 2012-2013 WIPO Re:Search Partnership Stories booklet is now available! This publication features 26 WIPO Re:Search collaborations and two of the hosting opportunities facilitated by BVGH, WIPO, and the Australian government. The individual stories describe the formation of these collaborations and their early results and successes. Click here to download the booklet.

BVGH also completed its 2013 Partnership Hub Annual Report. The report documents BVGH's achievements and activities. New this year, the report features a Collaboration Pipeline Chart, which tracks each research program's status and development. WIPO Re:Search Members and followers can see where each collaboration began and monitor research and development progress. The Collaboration Pipeline Chart will be updated regularly by BVGH and can be found on our website. Click here to download the Report.

WIPO Re:Search Statistics
Cornerstones of Collaboration

Six new collaborations were finalized last month, including the following:

The University of California, San Francisco (UCSF) will determine the EC50 of Stanford’s set of anti-Leishmania peptides. Promising peptides will be assayed for their effect on the morphology of the parasite.

Pfizer agreed to provide PATH and The University of Vermont (UVM) with a compound to test a specific therapeutic hypothesis in an animal model of diarrheal disease.

GlaxoSmithKline will provide the National Institute of Immunology in India with kinase inhibitors to test against liver-stage malaria parasites.

Partnership Hub Central
Jennifer Dent, Roopa Ramamoorthi, and Katy Graef visited the University of British Columbia (UBC) last month. During the visit, they met with several researchers, including Hongshen Ma, Assistant Professor, Mechanical Engineering, Robert Hancock, Director, Centre for Microbial Disease and Immunity Research, and Kishor Wasan, Director, Neglected Global Diseases Initiative (NGDI-UBC). During their visit, the BVGH team discussed the scientists’ current research interests and suggested potential partnership opportunities with WIPO Re:Search Members.

From left to right: Brett Sharp, University-Industry Liaison Office, Roopa Ramamoorthi, Katy Graef, Kishor Wasan, Neglected Global Diseases Initiative (NGDI-UBC), Robert Hancock, Centre for Microbial Disease and Immunity Research, and Jocelyn Conway, NGDI-UBC.
New Member Announcement

This month, we are pleased to announce that Kineta® has joined WIPO Re:Search.

Located in Seattle, Kineta is a nationally-recognized biotechnology company focused on developing cutting-edge therapeutics for autoimmune diseases, viral diseases, and chronic pain. Kineta has developed several small molecule anti-viral candidates that target the innate immune system. These molecules may be useful against a range of viruses, including influenza, dengue, and West Nile viruses. The biotechnology company is also utilizing its innate immune response platform to design adjuvants for both therapeutic and preventative vaccines.

"Partnership is a core element of our drug development strategy and values at Kineta," says Charles Magness, CEO and President of Kineta. "Our team looks forward to leveraging the WIPO Re:Search network and BVGH’s support to help advance our vaccine and neglected disease programs."

Research Request

WIPO Re:Search Supporter Member, the Council on Health Research for Development (COHRED) is continuing their work aimed at building negotiation capacity in research contracting for organizations in low- to-middle-income countries (LMICs). COHRED is compiling case studies of experiences from individuals living in LMICs that demonstrate various approaches to negotiating fair and equitable research contracts. If you have a contracting experience you wish to share, please contact Jacintha Toohey.

Highlighted Contributions

Featured this month are three contributions submitted by the University of South Florida (USF) to the WIPO Re:Search Database.

Synthetic Duffy binding protein-based vaccine
USF has developed a novel synthetic vaccine based on the ligand domain of the *P. vivax* Duffy binding protein (DBP). The vaccine elicits antibodies with functional activity against broader allelic variants of the DBP, and favors boosting responses against conserved protective epitopes.

Novel compound for development of anti-malarial drug
USF has developed a compound that displays potent anti-malarial activity and improved chemical resistance to multi-drug resistant malaria parasites. The 4(1H)-quinolone has shown activity at concentrations as low as 0.15nM against multi-drug resistant *P. falciparum*. 
Nanoparticles to enhance antibiotic delivery and performance
These nanoparticles protect and promote the delivery of antibiotic drugs. Antibiotic drugs are either chemically bonded to, or encapsulated by, the polyacrylate nanoparticles. These nanoparticle antibiotics are morphologically consistent and enhance bioactivity of water-soluble and water-insoluble antibiotics. These nanoparticles have also been tested for their delivery of antimalarial drugs.

The full description of these contributions will be available within the Database soon.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

WIPO Re:Search in the News

The Nigerian Law Intellectual Property Watch website highlighted the WIPO Re:Search video featuring Wellington Oyibo, Associate Professor, College of Medicine, University of Lagos. The article and video can be seen here.

WIPO Director General, Francis Gurry, mentioned WIPO Re:Search during an interview that was published during the lead-up to the WIPO Coordination Committee’s nomination of the future WIPO Director General.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar. 16-21</td>
<td>Extending the Antibiotic Era - Gordon Conference</td>
<td>Ventura, CA</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 30 - Apr. 4</td>
<td>Novel Therapeutic Approaches to Tuberculosis - Keystone Symposium</td>
<td>Keystone, CO</td>
<td>Website</td>
</tr>
<tr>
<td>Apr. 2-5</td>
<td>16th International Congress on Infectious Diseases</td>
<td>Cape Town, South Africa</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event?
Do you have a Research Request to highlight in the Snapshot?

We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members
*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
April 2014

A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

Spring has sprung busier than ever for BVGH and WIPO Re:Search. Four new collaborations between Members were finalized.

If you haven't already done so, please visit our website to download a copy of the 2012-2013 WIPO Re:Search Partnership Stories and the 2013 Partnership Hub Annual Report.

I am extremely pleased to welcome our three newest Members, the National University of Singapore, the National Institute of Parasitic Diseases, Chinese CDC, and Salvensis. Each organization participates in cutting-edge neglected disease research and brings abundant collaboration opportunities to WIPO Re:Search.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH

Save the Date - 2014 WIPO Re:Search Annual Meeting
The WIPO Re:Search Annual Meeting will be held in New York City this year. The Meeting is scheduled to coincide with the 27th International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Assembly and is tentatively set for November 6th. Stay tuned for updates as the event draws nearer.

Special Notice

The 2014 Biotechnology Industry Organization (BIO) International Convention will be held June 23-26, in San Diego, California. This year's Convention will feature several fora, such as the Emerging Opportunities in Global Markets Forum: Africa and The Changing Landscape of Industry's Engagement in Global Health, that will include important discussions regarding the healthcare needs of the developing world. The Convention will provide the opportunity to engage industry leaders and budding start-ups in discussions about the necessity and feasibility of products for diseases of poverty and to raise global awareness of these diseases' devastating effects.

WIPO Re:Search Statistics

Cornerstones of Collaboration

Four new collaborations were finalized this month, including:

The University of British Columbia (UBC) will provide Swiss Tropical and Public Health Institute (Swiss TPH) with a selection of avermectins to screen against M. ulcerans, the causative agent of Buruli ulcer.

Partnership Hub Central

Christian Agyare, Senior Lecturer, Faculty of Pharmacy & Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana, is one of the five African scientists who have participated in sabbatical opportunities at WIPO Re:Search Members' locations. Christian was hosted by Conor Caffrey, Schistosomiasis and Hookworm Core Director, Center for Discovery and Innovation in Parasitic Diseases, University of California, San Francisco (UCSF). During the first stage of his visit, Christian screened small molecules and natural products against several pathogenic parasites. A video interview of Christian is available on WIPO's YouTube channel.
New Members Announcement

We are pleased to announce that the National University of Singapore (NUS), the National Institute of Parasitic Diseases (NIPD), Chinese CDC, and Salvensis have joined WIPO Re:Search.

The National University of Singapore is an institution considered to be among the best in the world. Its faculty members study numerous topics of importance to global health, including the development of mucosal dengue vaccines and tuberculosis chemotherapies.

Located in Shanghai, China, the National Institute of Parasitic Diseases, Chinese CDC, has been a WHO Collaborating Center for malaria, schistosomiasis, and filariasis for 30 years. Research at NIPD also includes projects focusing on soil-transmitted helminthiases and leishmaniasis.

Salvensis is a nonprofit drug discovery company focused on rare and neglected diseases. The organization, which is located in Sandwich, UK is currently working to discover new and improved drugs to treat schistosomiasis.

Research Request
GlaxoSmithKline, in partnership with its Tres Cantos Open Lab Foundation (TCOLF) and funding from the European Commission, has announced the establishment of its new Open Lab Cofund Fellowship Program. The program seeks to provide experienced researchers with the opportunity to develop research projects at GSK's facilities in Tres Cantos, Spain, which includes support from GSK's staff and access to its resources. For more information, visit the TCOLF Cofund page. The next application deadline is June 25th, 2014.

Highlighted Contributions

Featured this month are two contributions submitted by the Kenya Agricultural Research Institute (KARI), Trypanosomiasis Research Centre to the WIPO Re:Search Database.

Primate models for African trypanosomiasis (ID: 2842)
The Trypanosomiasis Research Centre (TRC) maintains significant animal testing facilities, including the capacity to hold up to 150 primates. TRC is looking to enter into collaborative partnerships, including contract research, for organizations wishing to undertake in vivo pre-clinical studies into the safety and toxicity of drug candidates and diagnostic tools, using its primate models.

Parasite Bank (ID: 2823)
The TRC is looking to develop partnerships with interested parties wishing to gain access to its comprehensive parasite bank, for the purposes of genetic sequencing and / or the development of new diagnostic tools and vaccines. The bank contains all human trypanosomes, all animal parasites, and DNA from trypanosome vectors.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 12-15</td>
<td>10th BioMalPar - Biology and Pathology of the Malaria Parasite</td>
<td>Heidelberg, Germany</td>
<td>Website</td>
</tr>
<tr>
<td>June 8-13</td>
<td>Molecular Mechanisms of Pathogenesis and Treatment of Parasitic Diseases</td>
<td>Newport, RI</td>
<td>Website</td>
</tr>
<tr>
<td>Jun 30 - July 2</td>
<td>Seventh EDCTP Forum - The Partnership Journey: New Horizon for Better Health</td>
<td>Berlin, Germany</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event? Do you have a Research Request to highlight in the Snapshot? We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members

*known as Merck in the US and Canada
A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

The past month has been bustling with activities and meetings. I traveled to Los Angeles to attend the 2014 Milken Institute Global Conference. During the event, I spoke with individuals from the NIH, IAVI, and Chevron about WIPO Re:Search and the impact that private industry and academics are having on global health. WIPO Re:Search activities and achievements were met with interest and excitement.

I am happy to announce that WIPO Re:Search has reached its 60th collaboration. These 60 partnerships encompass 13 diseases, and involve 38 of our Member organizations.

The 2014 BIO international Convention is next month in San Diego, CA. I will be moderating two panels: Africa: The Next Biotech Frontier? and The Changing Landscape of Industry's Engagement in Global Health. WIPO Director General, Francis Gurry, will be giving the IP Session keynote lecture and participating on the Scientific American panel, as well as in a private session coordinated by BIO and BVGH.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

Save the Date - 2014 WIPO Re:Search Annual Meeting

The WIPO Re:Search Annual Meeting will be held in New York City this year. The Meeting is scheduled to coincide with the 27th International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Assembly and is tentatively set for November 6th. Stay tuned for updates as the event draws nearer.
Special Notice

The 2014 Biotechnology Industry Organization (BIO) International Convention will be held June 23-26, in San Diego, California. WIPO Re:Search will be highlighted in the following panel sessions, moderated by Jennifer Dent:

**The Changing Landscape of Industry’s Engagement in Global Health** (June 25th, 2014, 8:30am - 10:00am)

Participants:
Robert DeBerardine, Senior Vice President & General Counsel, Sanofi
Wim Leereveld, CEO and Founder, Access to Medicine Index

**Africa: The Next Biotech Frontier?** (June 25th, 10:15am - 11:45am)

Participants:
Richard Gordon, Director, Strategic Health Innovation Partnerships (SHIP), MRC South Africa
Dennis Liotta, Samuel Chandler Dobbs Professor of Chemistry, Emory University
Solomon Nwaka, Director, African Network for Drugs and Diagnostics Innovation (ANDI), World Health Organization

WIPO Re:Search Statistics

Cornerstones of Collaboration

Four new collaborations were finalized this month, including:

Eisai will provide a set of inhibitors to the Liverpool School of Tropical Medicine (LSTM) to examine inflammation induced by *Plasmodium*-infected red blood cell adherence to vascular endothelial cells.

Momar Ndao, Assistant Professor, Department of Medicine, McGill University, will provide Leonard Foster, Director, Centre for High-Throughput Biology, University of British Columbia (UBC), with frozen extracts of *T. cruzi*-infected and *Cryptosporidium*-infected cells. UBC will use these extracts to identify novel vaccine antigens for Chagas disease and cryptosporidiosis.

Horacio Bach, Adjunct Professor, Division of Infectious Diseases, University of British Columbia, will utilize its phage display technologies to develop new antibodies against Chagas disease host biomarkers identified by
Momar Ndao, McGill University. Once developed, the antibody will be incorporated into the development of a diagnostic.

**Partnership Hub Central**

Jennifer Dent attended the 2014 Milken Institute Global Conference in Los Angeles, CA. At the event, Jennifer spoke with Francis Collins, Director, **US National Institutes of Health**, and President Paul Kagame, President, Republic of Rwanda, about WIPO Re:Search and its partnership activities.

![Jennifer converses with President Kagame of the Republic of Rwanda](image)

Last month, Katy Graef presented an overview of WIPO Re:Search and its achievements during the 2014 British Society for Parasitology Spring Meeting in Cambridge, United Kingdom. During the meeting, Katy spoke with researchers from LSTM, **University of Dundee**, and Kingston University, London.

Roopa Ramamoorthi and Katy attended the 2014 Seattle Parasitology Conference, held by Seattle BioMed. They discussed current and future research plans with researchers from Seattle BioMed and the **University of Washington** (UW).
Roopa and Katy met with Kim Woodrow, Assistant Professor, Dan Ratner, Associate Professor, and Charles McLien III, Director, UW Bioengineering Affiliates Program, from the UW Bioengineering department. Kim and Dan presented their research interests and priorities, and discussed their partnership interests and possible WIPO Re:Search partnerships.

BVGH also met with Kristin Bedard, Director and Head of Virology, Chelsea Olsen, Associate Director, Program Management & Virology, and Dan Eramian, Senior VP Corporate Communications & Investor Relations, from Kineta. Kristin and Chelsea presented Kineta's antiviral and innate immune adjuvant programs and current partners, as well as their partnership interests.

Highlighted Contributions
Featured this month are two contributions submitted by the ANDI Centre of Excellence for Malaria Diagnosis, University of Lagos, to the WIPO Re:Search Database.

**In vitro and in vivo platforms for screening crude plant extracts against parasitic agents (ID: 2685)**

In vitro and in vivo platforms to screen plant crude extracts for anti-parasitic activities are being set up. The University is willing to collaborate to develop quality crude plant extracts with anti-parasitic properties by sharing preliminary screening data.

**Access to malaria diagnostic evaluation (ID: 2701)**

The University of Lagos has strong capacity for malaria diagnostic evaluation. It is actively involved in research, capacity building, and diagnostic test/reagent evaluation. The University can provide Members with access to invasive (blood) and non-invasive (urine, saliva) samples to evaluate malaria diagnostics based on immunological, nucleic acid, and other platforms.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

### Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 8 - 13</td>
<td>Molecular Mechanisms of Pathogenesis and Treatment of Parasitic Diseases</td>
<td>Newport, RI</td>
<td>Website</td>
</tr>
<tr>
<td>June 23-26</td>
<td>2014 BIO International Convention</td>
<td>San Diego, CA</td>
<td>Website</td>
</tr>
<tr>
<td>Jun 30 - July 2</td>
<td>Seventh EDCTP Forum - The Partnership Journey: New Horizon for Better Health</td>
<td>Berlin, Germany</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event?  
Do you have a Research Request to highlight in the Snapshot?  
We want to hear from you! Please send feedback and suggestions via email.

**WIPO Re:Search Pharmaceutical Members**

*Known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.
A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

BVGH will celebrate its ten year anniversary this month at the 2014 BIO International Convention in San Diego. BIO is sure to be as meaningful as ever, and will feature keynote speakers Hillary Clinton, Richard Branson, Francis Gurry (WIPO), and BVGH Board members, James Greenwood and Steven Burrill.

BVGH will be managing several important events this year at the 2014 BIO International Convention. I will be moderating two panel sessions, including Africa: The Next Biotech Frontier? and The Changing Landscape of Industry's Engagement in Global Health. WIPO Director General, Francis Gurry, will be giving the Intellectual Property Session keynote lecture and participating on the Scientific American Panel, as well as speaking to CEOs and Executives at a private session co-hosted by BIO and BVGH.

Another important event will also occur this month. The Washington Biotechnology and Biomedical Association (WBBA) is hosting the 2014 Life Sciences Innovation Northwest conference (LSINW) in Seattle. This event is North America’s largest, fully-integrated, life science expo.

Roopa Ramamoorthi, Katy Graef, and I will be at the 2014 BIO International Convention; we look forward to meeting you there as well as in Seattle at the LSINW conference!

I am pleased to welcome our two newest WIPO Re:Search Members, the University of Edinburgh and the University of Yaoundé I.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
The 2014 Biotechnology Industry Organization (BIO) International Convention will be held June 23-26, in San Diego, California. WIPO Re:Search will be highlighted in the following panel sessions, moderated by Jennifer Dent:

**The Changing Landscape of Industry’s Engagement in Global Health** (June 25th, 2014, 8:30am - 10:00am)

**Participants:**
Robert DeBerardine, Senior Vice President & General Counsel, Sanofi
Charlotte Hubbert, Program Investment Officer, Venture Investing, Bill & Melinda Gates Foundation
Charles Magness, President & CEO, Kineta, Inc.
David Olsen, Head of External Partnerships Infectious Disease, MSD*
Fred Tonelli, Head of External Innovation, Global Public Health, Johnson & Johnson's Janssen R&D

**Africa: The Next Biotech Frontier?** (June 25th, 10:15am - 11:45am)

**Participants:**
Richard Gordon, Director, Strategic Health Innovation Partnerships (SHIP), MRC South Africa
Dennis Liotta, Samuel Chandler Dobbs Professor of Chemistry, Emory University
Solomon Nwaka, Director, African Network for Drugs and Diagnostics Innovation (ANDI), World Health Organization
Mboneni Muofhe, Deputy Director General, Technology Innovation, Dept. of Science and Technology, South Africa Nigerian National Universities Commission (NUC) Representative

*Known as Merck in the US and Canada

**WIPO Re:Search Statistics**

<table>
<thead>
<tr>
<th>Agreements</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>63</td>
<td>85</td>
</tr>
</tbody>
</table>

**Cornerstones of Collaboration**

Three new partnerships were finalized this month, including:

Alnylam will provide Aberystwyth University with lipophilic in vivo siRNA delivery reagents, which will be used by researchers at Aberystwyth University to examine the effect of gene knockdown in schistosome worms.

**New Member Announcement**

We are pleased to announce that the University of Edinburgh and the University of Yaoundé I have joined WIPO Re:Search.
The University of Edinburgh, located in Scotland, United Kingdom, is home to the Edinburgh Infectious Diseases (EID) network. The EID includes over 150 Principal Investigators and 760 active researchers across the field of infectious disease. Research projects within the EID include the immunology of helminth infections, malaria pathogenesis and vaccines, and disease progression in trypanosome infections.

Located in Yaoundé, Cameroon, the University of Yaoundé I has eight departments within its Faculty of Medicine and Biomedical Sciences, including the Centre for Implementation and Community-Based Research (CICBR) and the Laboratory of Bioorganic and Medicinal Chemistry (LABIOMED). Research at the University includes examining the antibacterial, anti-malarial, and anti-trypanosomal activities of natural products.

**Partnership Hub Central**

Tom Bombelles, Head, Global Health, WIPO, presented WIPO Re:Search and chaired a panel on Open Innovation at the International Society for Neglected Tropical Diseases’ (ISNTD) Drug Discovery and Development (ISNTD d3) meeting in London. The conference attracted an impressive group of scientists committed to NTD research, including researchers from seven WIPO Re:Search Members. WIPO’s participation served to raise awareness of the Consortium, and also to recruit new Members.

From left to right: Tom Bombelles (WIPO), Paul Willis (MMV), Michael Pollastri (Northeastern University), Charles Mowbray (DNDi), John Overington (EMBL-EBI), Raymond Hui (SGC), Barbara Holtz (Collaborative Drug Discovery), and Lluís Ballell-Pages (GSK Tres Cantos Open Lab)

Katy Graef gave a presentation introducing global health, WIPO Re:Search, and diagnostic platforms developed to address diseases.
of the developing world at the **University of Washington** Bioengineering department weekly seminar.

Katy presents global health measurements at the University of Washington.

**Member Spotlight**

Olfat Hammam, Professor of Pathology, **Theodor Bilharz Research Institute** (TBRI), finished her one-year sabbatical at **Stanford University** in the laboratory of Michael Hsieh, Assistant Professor of Urology. Her research project, which focused on schistosomal bladder carcinogenesis and fibrosis, culminated in the acceptance of two articles for publication. Their *PLOS NTDs* article can be found [here](#) and their *Trends in Parasitology* article can be found [here](#). Congratulations Olfat, Michael, and the Hsieh lab!
Michael Hsieh and Olfat Hammam
Highlighted Contributions

Featured this month are two contributions submitted by Sanofi to the WIPO Re:Search Database.

**Eflornithine samples for R&D purpose (ID: 1361)**
Sanofi can provide Members with information regarding Eflornithine, including clinical and pharmacological data, as well as samples for R&D. Eflornithine is a WHO-recommended treatment for human African trypanosomiasis (HAT).

**Erythromycin compounds, their process of preparation, and their application as medicaments (ID: 1204)**
Sanofi can provide the patents related to erythromycin compounds - macrolides with antibiotic properties. These patents include the compounds’ process of preparation as well as experimental data.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

WIPO Re:Search in the News

Jennifer Dent was quoted in a recent press release from WIPO Re:Search Member, Kineta, Inc.. The release announced new data demonstrating activity of Kineta’s innate immune response agonist against dengue virus serotype 2 in vivo. These agonists, which target IRF-3, have the potential to inhibit a diverse range of viruses.

WIPO Re:Search was mentioned in the 2014 Special 301 Report published by the United States Trade Representative. The Report, which presents the state of intellectual property rights (IPR) worldwide, briefly describes WIPO Re:Search within its "Best IPR Practices by Trading Partners" subsection.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 23-26</td>
<td>2014 BIO International Convention</td>
<td>San Diego, CA</td>
<td>Website</td>
</tr>
<tr>
<td>June 30 - July 2</td>
<td>Seventh EDCTP Forum - The Partnership Journey: New Horizon for Better Health</td>
<td>Berlin, Germany</td>
<td>Website</td>
</tr>
<tr>
<td>July 13 - 18</td>
<td>Gordon Conference: An Interdisciplinary Approach to Tackling Drug Resistance Across Disease States</td>
<td>Newry, ME</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event?
Do you have a Research Request to highlight in the Snapshot?

We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members
*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

It is hard to believe that the year is halfway over. Since January, 22 new partnerships have been established and eight new Members have joined the Consortium. Visit here for a glimpse at the geographical distribution of the WIPO Re:Search partnerships and Members. BVGH is in the process of updating the WIPO Re:Search Collaboration Pipeline, so if you have a WIPO Re:Search partnership in place, be on the lookout for an email from Roopa Ramamoorthi or Katy Graef, who are compiling the updates.

WIPO Director General, Francis Gurry, attended the 2014 Biotechnology Industry Organization (BIO) International Convention in San Diego. During the event, Francis participated on the Scientific American Worldview Super Session panel, as well as at a private session organized by BIO and BVGH. He discussed his next term and his support and appreciation for WIPO Re:Search at this private event. BVGH also organized a panel session to discuss the biopharmaceutical industry’s participation in global health initiatives. The panel featured representatives from three Consortium Members.

I am pleased to welcome our newest Member, the Centre Pasteur du Cameroun.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Special Announcement - Save the Date

The 2014 WIPO Re:Search Annual Meeting will be held in New York City on November 6th. The Meeting is scheduled to coincide with the 27th International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Assembly. Prior to the Annual Meeting (Nov. 4-5th), WIPO will hold a two-day IP Workshop open to all Members.

WIPO Re:Search Statistics

<table>
<thead>
<tr>
<th>Agreements</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>86</td>
</tr>
</tbody>
</table>

Cornerstones of Collaboration

Three new partnerships were finalized this month, including:

The University of Lagos will provide Novartis with dry blood spots from malaria patients. Novartis will assess the feasibility of using dried blood spot sampling (DBSS) and next generation sequencing of Plasmodium falciparum in malaria patients in Nigeria.
Dr. Ravi Selvaganapathy, Associate Professor, McMaster University, will develop a filtration device capable of concentrating particulates from environmental samples. Once completed, Dr. Ricardo Izurieta, Associate Professor, University of South Florida, will assess the device’s ability to concentrate Ascaris eggs from soil and sewage samples.

New Member Announcement

We are pleased to announce that the Centre Pasteur du Cameroun has joined WIPO Re:Search.

Located in Yaoundé, Cameroon, the Centre Pasteur du Cameroun, is composed of seven sections, including the Laboratory of Virology, and the Laboratory of Mycobacteria. Research within the Centre includes the examination of the geographical distribution of filariasis in Cameroon and the molecular characterization of multi-drug resistant M. tuberculosis strains.

Partnership Hub Central

Jennifer Dent, Roopa Ramamoorthi, and Katy Graef attended the 2014 BIO International Convention in San Diego. Jennifer moderated a panel, The Changing Landscape of Industry’s Engagement in Global Health, which featured panelists from Sanofi, the Bill & Melinda Gates Foundation, Kineta, Inc., MSD*, and Johnson & Johnson’s Janssen R&D. The panelists described their organization's global health initiatives and shared their experiences participating in various programs including, WIPO Re:Search. The necessity of collaborations to advance global health R&D was a core focus of the discussion.

While at the Convention, Jennifer, Roopa, and Katy discussed collaboration opportunities with current Members, including 60 Degrees Pharmaceuticals (60P) and the University of Edinburgh.
The Changing Landscape of Industry's Engagement in Global Health panel. From left to right: Robert DeBerardine (Sanofi), Fred Tonelli (Johnson & Johnson's Janssen R&D), Charlotte Hubbert (Bill & Melinda Gates Foundation), David Olsen (MSD), Chuck Magness (Kineta, Inc.), and Jennifer Dent (BVGH)

*Known as Merck in the US and Canada

**Member Spotlight**

Stanford University SPARK program co-directors, Daria Mochly-Rosen and Kevin Grimes, published, "A Practical Guide to Drug Development in Academia", which is designed for academics interested in learning about the drug development process and how they can translate their findings into medical products. Topics range from repurposing drugs and developing high-throughput screens to pre-clinical safety studies and clinical trial design.
Highlighted Contributions

Featured this month are two contributions submitted by the Center for World Health & Medicine (CWHM) to the WIPO Re:Search Database.

**Malaria parasite growth assays (ID: 1921)**
The CWHM will consider requests to evaluate tool compounds and drug candidates for effects on Plasmodium parasite growth in human erythrocytes in vitro. Potential for drug resistance and synergy with standard treatment agents can also be explored.

**High-throughput assay development and screening (ID: 1882)**
The CWHM will consider collaborative proposals to develop and optimize target-based or phenotypic assays to identify compounds as useful probes for neglected disease programs. Partners may request screening of available compound collections or provide their own. Lead optimization resources are also available.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

WIPO Re:Search in the News

SciDev.Net published an article discussing the impact that WIPO Re:Search has had on neglected disease research to date.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 24-27</td>
<td>89th Annual Meeting of the American Society of Parasitologists</td>
<td>New Orleans, LA</td>
<td>Website</td>
</tr>
<tr>
<td>August 10-15</td>
<td>13th International Congress of Parasitology (ICOPA XIII)</td>
<td>Mexico City, Mexico</td>
<td>Website</td>
</tr>
<tr>
<td>August 31 - Sept. 5</td>
<td>International Conference on NanoMaterials (ICNM 2014)</td>
<td>Flic en Flac, Mauritius</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event?  
Do you have a Research Request to highlight in the Snapshot?
We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members

*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

SafeUnsubscribe™

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Rapid removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
August 2014

In This Issue
Special Announcement
WIPO Re:Search Statistics
Cornerstones of Collaboration
New Members Announcement
Partnership Hub Central
Highlighted Contribution
WIPO Re:Search in the News
Upcoming Global Health Events

A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

I hope everyone is enjoying time with family and friends during this beautiful summer. Our team at BVGH are busy identifying new partnership opportunities for our WIPO Re:Search Members and many of these are developing into promising collaborations for neglected diseases. Last month, three new partnerships were finalized, bringing our 2014 total to 25 new WIPO Re:Search agreements. To learn more about BVGH’s activities and achievements from the first half of this year, download our 2014 Partnership Hub Mid-Year Report.

I am pleased to welcome our two newest Members, the Walter and Eliza Hall Institute of Medical Research and Washington University in St. Louis.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

Stay Connected

BVGH Website
WIPO Re:Search Database
Special Announcement - Save the Date

The 2014 WIPO Re:Search Annual Meeting will be held in New York City on November 6th. The Meeting is scheduled to coincide with the 27th International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Assembly. Prior to the Annual Meeting (Nov. 4-5th), WIPO will hold a two-day IP Workshop open to all Members.

WIPO Re:Search Statistics

![Agreements and Members](image)

Cornerstones of Collaboration

Four researchers from WIPO Re:Search Member institutions participated in sabbatical opportunities - supported by the Australian government - at three WIPO Re:Search Members’ locations last year. Fidelis Cho-Ngw a, Associate Professor of Biochemistry, University of Buea, participated in a three-month sabbatical at Novartis' headquarters in Basel, Switzerland. With a grant from the Japanese government, WIPO has prepared a video that presents Fidelis' onchocerciasis research and how he hopes to apply the skills that he learned at Novartis to his search for new drugs to treat the parasitic infection.
New Members Announcement

We are pleased to announce that the Walter and Eliza Hall Institute of Medical Research and Washington University in St. Louis have joined WIPO Re:Search.

The Walter and Eliza Hall Institute of Medical Research (WEHI) is the oldest medical research institute in Australia. WEHI focuses on translating cancer, chronic inflammatory diseases, and infectious diseases research into improved health outcomes for patients. Malaria, leishmania, HIV, and tuberculosis are some of the infectious diseases of interest to WEHI's scientists.

Washington University in St. Louis faculty members study numerous topics of importance to global health, including the genetics of *Leishmania major*, host-pathogen interactions of *Mycobacterium tuberculosis*, erythrocyte invasion by *Plasmodium*, and pathogenesis of
dengue viruses.

**Partnership Hub Central**

Jennifer Dent presented WIPO Re:Search as an example of industry’s participation in public sector global health initiatives during the *EDCTP and CAAST-Net Plus: Building Bridges* panel at the Seventh European & Developing Countries Clinical Trials Partnership (EDCTP) Forum in Berlin, Germany early last month. A report on the panel can be found [here](#).

![Image of participants at the EDCTP forum](image-url)

From left to right: Katharina Kuss (FCSAI), Jude Aidam (West African Health Organisation), Jennifer Dent (BVGH), Ole Olesen (EDCTP), Claudia Schacht (Fit for Health 2.0), Mboneni Muofhe (Dept. of Science and Technology, South Africa), Philippe Leissner (bioMerieux), Gift Mphefu (Med-Tech Engineers), Ana Lúcia Cardoso (EDCTP), Gatama Gichini (Ministry of Higher Education, Science and Technology, Kenya), John Mugabe (University of Pretoria)

**Highlighted Contribution**

Featured this month is a contribution submitted by the *University of Edinburgh* to the *WIPO Re:Search Database*.

*New antigens for malaria vaccine development and drug discovery (ID: 2941)*
PfEMP1 is a key *Plasmodium falciparum* surface molecule implicated in the development of severe malaria. Antibodies to unique antigenic domains of PfEMP1 stimulate cross-strain immunity to both lab strains and clinical isolates of *P. falciparum*. These antigens could be effective targets for new therapeutic strategies to treat or prevent severe malaria. This technology is available from the University of Edinburgh for license and/or research collaboration with a commercial partner able to support development of a treatment for severe malaria.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

**WIPO Re:Search in the News**

BVGH published an [Op-Ed article](#) in the *Seattle Times* that describes WIPO Re:Search and its unconventional approach to developing products for diseases of poverty.

**Upcoming Global Health Events**

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aug. 10-15</td>
<td>13th International Congress of Parasitology (ICOPA)</td>
<td>Mexico City, Mexico</td>
<td>Website</td>
</tr>
<tr>
<td>Aug. 31 - Sept. 5</td>
<td>International Conference on NanoMaterials (ICNM2014)</td>
<td>Flic en Flac, Mauritius</td>
<td>Website</td>
</tr>
<tr>
<td>Sept. 14-18</td>
<td>25th Annual Molecular Parasitology Meeting (MPM)</td>
<td>Woods Hole, Massachusetts</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event? Do you have a Research Request to highlight in the Snapshot?

We want to hear from you! Please send feedback and suggestions via [email](mailto:).

**WIPO Re:Search Pharmaceutical Members**
*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Rapid removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

With summer behind us, we are looking forward to a very busy season ahead. This includes the 3rd annual WIPO Re:Search meeting, which will be held on November 6th at Pfizer's headquarters in New York City.

Roopa Ramamoorthi will present WIPO Re:Search at the First COST Action CM 1307 Annual Meeting and represent the Consortium at the 63rd ASTMH Annual Meeting. Ujwal Sheth and Katy Graef will present a poster featuring WIPO Re:Search collaborations and attend The Modes of Action of Vaccine Adjuvants Keystone Symposium. If you are planning to attend one of these meetings, I encourage you to contact Katy to set up a meeting to discuss your research and partnering interests.

I am pleased to welcome our two newest Members, the University of California, San Diego (UC San Diego) and the Biomedical Research Institute (BRI).

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Special Announcement - WIPO Re:Search Database

If you have an asset of relevance to neglected disease research that you wish to contribute to the WIPO Re:Search Database, please email Phil Stevens at WIPO.

WIPO Re:Search Statistics

Cornerstones of Collaboration

Eight new partnerships were finalized last month, including:

Alnylam will help Dr. Deepak Kaushal, Professor of Microbiology and Immunology, Tulane University, with optimal design of siRNAs against a host protein expressed in macrophages during infection. Deepak will assess the effect that knockdown of this protein will have on M. tuberculosis infection in vitro and in a non-human primate model of infection.

Dr. Wellington Oyibo, Associate Professor, College of Medicine, University of Lagos, will collaborate with Dr. Jun-Hu Chen, Vice Chief & Associate Professor, Key Laboratory of Vector and Parasite Biology, National
Institute of Parasitic Diseases (NIPD), Chinese Center for Disease Control and Prevention (China CDC), to identify resistance to anti-malarial drugs using dry blood spots from Nigerian malaria patients treated with anti-malarials. Jun-Hu will host a PhD student of Wellington for two months. During this time, they will utilize the dried blood to monitor drug resistance markers (DHFR and DHPS genes for Sulphadoxine pyremethamine resistance and PFMDR1 and PFCRT genes for Chloroquine resistance) in the Plasmodium parasites contained within the samples.

New Members Announcement

We are pleased to announce that the University of California, San Diego (UC San Diego) and the Biomedical Research Institute (BRI) have joined WIPO Re:Search.

The University of California, San Diego (UC San Diego) is a research-focused public institution, recognized as one of the top research universities in the world. It has numerous divisions and departments of relevance to WIPO Re:Search including its Skaggs School of Pharmacy and Pharmaceutical Sciences and its Division of Infectious Diseases. Dengue, malaria, and tuberculosis are some of the infectious diseases being studied at UC San Diego.

Located in Rockville, Maryland, the Biomedical Research Institute (BRI) is a nonprofit organization committed to improving global health. BRI houses the NIAID/NIH Schistosomiasis Resource Center, which has the three major schistosome species. The Institute also develops molecular reagents for schistosomiasis research and offers a semiannual training course that focuses on the maintenance of Schistosoma species life cycle.

Member Spotlight

PUBLIC INTEREST INTELLECTUAL PROPERTY ADVISORS (PIIPA) is an NGO serving as a clearinghouse for global public interest intellectual property (IP). Its core activity involves a global network that links people who need IP assistance with IP professionals. PIIPA's volunteer IP professionals offer pro bono assistance to individuals, communities, small enterprises, government agencies, and institutes from developing countries or whose work benefits developing countries and communities. To learn more about PIIPA's program and to apply for IP assistance please visit its website.

Member Announcement
Highlighted Contribution

Featured this month is a contribution submitted by the National University of Singapore to the WIPO Re:Search Database.

Collaboration in developing anti-tuberculosis compounds (ID: 2962)

Professors Thomas Dick and Nick Paton at the National University of Singapore have the capacity to develop anti-tuberculosis compounds all the way from target discovery to proof of concept, preclinical, and clinical development. They are interested in exploring potential collaborations around chemically validated targets and have the capability for target identification for compounds with interesting whole cell activity. They are also interested in speaking with researchers with advanced compounds and optimized leads, and can support preclinical development if there is mutual interest, including PK, PD, rat toxicity studies, and formulation development. Compounds modulating host response should be ready to begin clinical trials.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept. 14-15</td>
<td>Innovation in Global Health: Bridging the Innovation Gap between Research and Implementation</td>
<td>Chapel Hill, NC</td>
<td>Website</td>
</tr>
<tr>
<td>Oct. 8-13</td>
<td>Keystone Symposium: The Modes of Action of Vaccine Adjuvants</td>
<td>Seattle, WA</td>
<td>Website</td>
</tr>
<tr>
<td>Nov. 2-6</td>
<td>American Society of Tropical Medicine and Hygiene (ASTMH) 63rd Annual Meeting</td>
<td>New Orleans, LA</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event? Do you have a Research Request to highlight in the Snapshot? We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members
*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

SafeUnsubscribe™

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Rapid removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

It is hard to believe, but this month WIPO Re:Search celebrates its third anniversary! In these three years, BVGH has facilitated 79 partnerships between Members. These partnerships involve 47 Members, representing 15 countries, and focus on 18 diseases, including dengue, Buruli ulcer, and schistosomiasis. BVGH is looking forward to the coming year and the new partnerships and Members that it will bring.

Last week I attended the 2014 Grand Challenges Meeting in Seattle. The meeting, which convened some of the best and brightest minds in global health, was an excellent opportunity to engage representatives from current WIPO Re:Search Member organizations as well as potential new Members.

Roopa Ramamoorthi will be attending the 63rd ASTMH Annual Meeting in New Orleans and Katy Graef and I will be at this year’s WIPO Re:Search Annual Meeting. If you would like to meet with us at either of these events, please email Katy.

I am pleased to welcome our two newest Members, the Noguchi Memorial Institute for Medical Research (NMIMR) and the Central University of Ecuador.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
Special Announcement - 2014 WIPO Re:Search Annual Meeting

The 2014 WIPO Re:Search Annual Meeting will be held on November 6th at Pfizer's global headquarters in New York City. Members may participate in person or via WebEx. To confirm your participation, email a completed attendance form to Claudette Safar Richa at WIPO.

Prior to the Annual Meeting (Nov. 4-5th), WIPO will hold a two-day workshop focusing on intellectual property management. For more information about this workshop, please email Tom Bombelles (WIPO).

WIPO Re:Search Statistics

![Chart showing WIPO Re:Search agreements and members statistics]

79 Agreements
92 Members

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Cornerstones of Collaboration

Two new partnerships were finalized last month, including:

Prof. Wei Hu, Head, Joint Laboratory of Genetics and Ecology of Parasite-Vector, National Institute of Parasitic Diseases (NIPD), Chinese Center for Disease Control and Prevention (China CDC), will provide Prof. Alexander Odaibo, Head, Parasitology Research
Unit, Faculty of Science, University of Ibadan, with a lateral flow dipstick diagnostic for schistosomiasis. Prof. Odaibo will assess the ability of the diagnostic, which was developed to diagnose S. japonicum infections, to diagnose S. mansoni infections.

New Members Announcement

We are pleased to announce that the Noguchi Memorial Institute for Medical Research (NMIMR) and the Central University of Ecuador have joined WIPO Re:Search.

Located in Accra, Ghana, the Noguchi Memorial Institute for Medical Research (NMIMR) is Ghana's leading biomedical research facility. In addition to providing specialized diagnostic and monitoring services, NMIMR scientists conduct research into diseases of importance to Ghana. This includes malaria, leishmania, Buruli ulcer, and viral hemorrhagic fevers.

"NMIMR has strong programs in malaria, HIV, tuberculosis, NTDs, and emerging infections such as influenza and viral hemorrhagic fevers. Another area of interest is medicinal plant research and there are groups interested in finding novel treatments for most of the pathogens that we work on. This program is what underlies our interest in joining WIPO Re:Search. Since our introduction to the family of WIPO and BVGH, we have experienced strong support from the team in Seattle and we are very grateful. As we look to the future, we expect to forge strong collaborations with established institutes to enable us to exploit the rich resources we have in Ghana. Already, the support we have had is a clear pointer that we will be able to travel this path, in the WIPO and BVGH family and establish a strong drug discovery program at the Institute." - Professor Kwadwo Koram, Professor & Director, NMIMR

The Central University of Ecuador, located in Quito, Ecuador, seeks to provide universal access to knowledge and culture. The scientists at the University's Center of Biomedicine conduct research of relevance to WIPO Re:Search including examining the anti-parasitic activities of native plants and the immunology and molecular biology of parasitic infections.

Partnership Hub Central

Jennifer Dent presented WIPO Re:Search at the 2014 Advances in Medicinal Plants Research in Ghana workshop held in Accra, Ghana. During her presentation, Jennifer described three WIPO Re:Search partnerships that involved screening natural products against M. tuberculosis, schistosomal worms, and soil-transmitted helminths.
Participants of the 2014 Advances in Medicinal Plants Research in Ghana. Attendees included: Prof. Oduro (Provost, UG), Dr. Daasebre Kweku Ewusi (GTMF), Prof. Koram (NMIMR), Dr. Appiah-Opong (NMIMR), Dr. Ekuazi (KNUST), Dr. Suzuki (NMIMR/TMDU), Prof. Yamaoka (TMDU), Dr. Ayi (NMIMR), Mr. Tanaka (JICA), Mrs. Adu-Amankwah (NMIMR), Prof. Nyarko (UG), Prof. Edoh (CSRPM), Mr. Arhin (TAMD, Ministry of Health), and Prof. Ohta (TMDU).

UG: University of Ghana; GTMF: Ghana Traditional Medicine Foundation; NMIMR: Noguchi Memorial Institute for Medical Research; KNUST: Kwame Nkrumah University of Science and Technology; TMDU: Tokyo Medical and Dental University; JICA: Japan International Cooperation Agency; CSRPM: Centre for Scientific Research into Plant Medicine; TAMD: Traditional & Alternative Medicine Directorate

Jennifer attended the 2014 Grand Challenges Meeting, which marked the ten year anniversary of the Grand Challenges award scheme. While at the meeting, Jennifer spoke with representatives from many current WIPO Re:Search Members including the University of California, San Francisco (UCSF), the Center for World Health & Medicine (CWHM), Seattle BioMed, and the Noguchi Memorial Institute for Medical Research (NMIMR).
BVGH published an article, "WIPO Re:Search: Catalyzing Collaborations to Accelerate Product Development for Diseases of Poverty", in a special global health edition of Chemical Reviews. The article, co-authored with Anatole Krattiger, Director, Global Challenges Division, WIPO, described five WIPO Re:Search partnerships, including an agreement between Pfizer and PATH.

**Member Spotlight**

The United States Patents & Trademark Office (USPTO) is accepting applications for its Patents for Humanity prize. This competition awards innovators that use patented technologies to address global challenges in five areas, including medicine. Winners receive recognition at a public awards ceremony and a certificate to accelerate one USPTO matter for any technology in their portfolio. The program is open to all types of businesses, researchers, and inventors - any patent holders or licensees may apply. Applications are due by Oct. 31, 2014.
Highlighted Contributions

Featured this month are two contributions submitted by the University of South Florida (USF) to the WIPO Re:Search Database.

Nanoparticles to enhance antibiotic delivery and performance (ID: 2881)
Researchers at USF are seeking partners to license their novel nanoparticles for the protection, rejuvenation, and delivery of antibiotic drugs. This methodology implements microemulsion polymerization as a means to easily prepare aqueous solutions of polyacrylate nanoparticles that contain antibacterial drugs either chemically bonded to the nanoparticle matrix or encapsulated within its protective core structure.

Design and Immunogenicity of a Novel Synthetic Antigen of the Plasmodium vivax Duffy Binding Protein (ID: 2902)
USF researchers are seeking partners to license their novel synthetic vaccine based on the ligand domain of the Plasmodium vivax Duffy binding protein (PvDBP). PvDBP is an essential ligand for parasite invasion of erythrocytes, making the molecule an attractive vaccine candidate against vivax malaria. However, allelic variation in the ligand domain may compromise vaccine efficacy by eliciting a strain-specific immune response. To overcome this inherent bias, USF researchers have designed a novel DBP-based vaccine that would elicit antibodies with functional activity against broader allelic variants and favor boosting responses against conserved protective epitopes.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

WIPO Re:Search in the News

WIPO Re:Search was mentioned in the article, "Emerging and Reemerging Neglected Tropical Diseases: a Review of Key Characteristics, Risk Factors, and the Policy and Innovation Environment", which was published in Clinical Microbiology Reviews. Tim Mackey et al. referenced WIPO Re:Search in their discussion of the new public-private partnerships paradigm for addressing emerging and re-emerging neglected tropical diseases.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov. 2-6</td>
<td>American Society of Tropical Medicine and Hygiene (ASTMH) 63rd Annual Meeting</td>
<td>New Orleans, LA</td>
<td>Website</td>
</tr>
<tr>
<td></td>
<td>Joint International Tropical Medicine Meeting (JITMM 2014)</td>
<td>Bangkok,</td>
<td></td>
</tr>
</tbody>
</table>
Are you attending a global health event?
Do you have a Research Request to highlight in the Snapshot?

We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members

*known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.
Dear WIPO Re:Search Members and Friends,

This month, WIPO held the 2014 WIPO Re:Search Annual Meeting at Pfizer's headquarters in New York City. Representatives from 21 Members participated in the event, including researchers from the Theodor Bilharz Research Institute, Centre Pasteur du Cameroun, and the University of Bamako. I presented BVGH's 2014 achievements - 37 new partnerships and 15 new Members - and our deliverables for 2015. A summary of our achievements and deliverables can be downloaded [here](#). At the Meeting, BVGH and WIPO officially welcomed our newest pharmaceutical company Member, Merck KGaA, and confirmed ongoing support from our other founding pharmaceutical Members.

While in New York City, I attended the 27th International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Assembly. This year's event, which convened global health leaders and government representatives, focused on how to meet the global demand of quality healthcare in a time of constrained resources.

BVGH team member, Ujwal Sheth, will be presenting WIPO Re:Search at the 2014 Joint International Tropical Medicine Meeting in Bangkok, Thailand next month. If you will be in attendance and would like to speak with Ujwal about collaboration opportunities, please send her an email.

I am pleased to welcome our two newest Members, Merck KGaA and the University of Ghana.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Special Announcement

Do you know someone at your institution doing neglected tropical disease, malaria, or tuberculosis research? If so, please forward our Snapshot along!

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

Cornerstones of Collaboration

Dr. Benjamin Pinsky, Assistant Professor of Pathology and Medicine, and Dr. Jesse Waggoner, Instructor of Medicine, at the Stanford University School of Medicine, are hosting Ms. Chika Celen Okangba, a doctoral student from the University of Lagos. Chika is a student of Dr. Wellington Oyibo, Associate Professor, College of Medicine, University of Lagos. Chika will spend two months working with Drs. Pinsky and Waggoner screening samples from patients from Lagos, Nigeria that presented with undifferentiated febrile illness. Following the identification of the pathogens causing the febrile illnesses, Chika will develop a customized PCR-based diagnostic targeting the most common pathogens in Lagos. To learn more, click here.
Three new partnerships were finalized last month, including:

Dr. Peter Brophy, Professor of Parasitology, Aberystwyth University, will provide Dr. Fidelis Cho-Ngwa, Associate Professor of Biochemistry, University of Buea, with Sigma class glutathione transferase (GST) inhibitors that had previously been shown to be
active against *Fasciola hepatica*. Fidelis will screen these inhibitors against *Onchocerca* microfilariae and macrofilariae, as well as *Loa loa* microfilariae.

Emory University scientists will collaborate with scientists from the Walter Reed Army Institute of Research (WRAIR) to measure the plasmablast response induced in human subjects following administration of two candidate dengue vaccines. Researchers will first vaccinate with a live-attenuated dengue vaccine and then "boost" with a purified inactivated dengue vaccine. WRAIR and GlaxoSmithKline (GSK) co-developed both of these candidate vaccines.

**New Members Announcement**

We are pleased to announce that the **University of Ghana** and **Merck KGaA** have joined WIPO Re:Search.

The University of Ghana is the oldest and largest public university in Ghana. The University is home to several departments with research of relevance to WIPO Re:Search including its Centre for Tropical Clinical Pharmacology & Therapeutics. Current research projects include studies of malaria pathogenesis and chemotherapy, population pharmacokinetics, and pharmacogenetics.

Merck KGaA (known as EMD in the US and Canada) is a leading pharmaceutical, chemical, and life-science company, headquartered in Darmstadt, Germany. Its biopharmaceuticals division focuses on transforming science into medical solutions for neurodegenerative diseases, fertility and metabolic endocrinology disorders, oncology, and autoimmune/inflammatory diseases.

Merck KGaA has demonstrated its commitment to improving the health of underserved populations by enhancing availability, accessibility, and affordability of medical products. It has dedicated a part of its R&D efforts to finding solutions for unmet medical needs of the developing world, with a focus on NTDs, malaria, and diarrheal diseases. Merck KGaA is the co-developer of praziquantel, the gold-standard treatment for schistosomiasis. Since 2007 Merck KGaA has donated millions of praziquantel tablets to the WHO for treatment of African school-aged
children. In 2012 Merck KGaA partnered with Astellas Pharma, Farmanguinhos, Simcyp, Swiss Tropical and Public Health Institute (Swiss TPH), and TI Pharma to establish the Pediatric Praziquantel Consortium. The mission of this consortium is to reformulate praziquantel for use in preschool-aged children.

Several Merck KGaA drugs are of relevance to WIPO Re:Search Members including its novel combination of pimasertib + PI3K inhibitor, which may be of use against parasitic diseases such as malaria, leishmaniasis, and human African trypanosomiasis. Its c-met kinase inhibitor and hypoxia-targeted drug may also be of use against parasitic diseases. Merck KGaA has developed vaccine and drug delivery systems, such as its easypod® automated drug delivery device and cool.click® 2 needle-free delivery device. Its phage-display technology can be of use to the development of antibodies for neglected disease diagnostics, while its overall expertise in pharmaceutical discovery and development will be beneficial to all aspects of WIPO Re:Search Members' neglected disease R&D.

**Partnership Hub Central**

Roopa Ramamoorthi presented a poster describing WIPO Re:Search and its successes at this year’s American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in New Orleans. During the conference Roopa met with representatives from WRAIR, GSK, Seattle BioMed, Novartis, and MSD*. 

Roopa also gave an oral presentation about WIPO Re:Search and moderated a panel discussion at the 1st Annual COST Action meeting in Calvi, France. The panel session, which featured representatives from GSK, Sanofi, the University of Nebraska Medical Center, and the University of Laval, focused on how industry and academia can collaborate, as well as the expertise each sector brings to a partnership.

*Known as Merck in the US and Canada

**Highlighted Contributions**

Featured this month are two contributions submitted by the National Institute of Parasitic Diseases (NIPD) (Chinese CDC) to the WIPO Re:Search Database.
Diagnostic Tests for Liver Flukes (ID: 2981)
Dr. Xue-nian Xu’s group has developed the Cs1 rapid diagnostic immunochromatographic test strip to diagnose patients infected with *Clonorchis sinensis* (Chinese liver fluke), the causative agent of clonorchiasis. *C. sinensis* is transmitted to humans through consumption of undercooked, smoked, pickled, and salted freshwater fish. Dr Xu’s group is also developing a kit to directly detect a *C. sinensis* antigen. This kit may be able to detect the liver fluke in uncooked fish. Dr. Xu is interested in collaborating with groups around these diagnostic tests.

Protein microarray for identifying biomarkers (ID: 2961)
Dr. Jun-Hu Chen and others have developed a protein microarray that can be used for identifying biomarkers for potential use in malaria parasite diagnostic and vaccine development.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

Member Spotlight
In early 2014, building upon the success of its Open Lab initiative in Tres Cantos, Spain, GlaxoSmithKline (GSK) launched a similar Open Lab initiative focused on supporting research into non-communicable diseases (NCDs) in Africa. The Africa NCD Open Lab aims to understand how and why NCDs manifest differently in Africa through high-quality epidemiological, genetic, and interventional research, while building local disease expertise in Africa. GSK launched its first call for Africa NCD Open Lab research proposals. Researchers from the Côte d'Ivoire, Cameroon, Ghana, The Gambia, Nigeria, Kenya, Uganda, and Malawi are eligible to apply. For more information, click here.

WIPO Re:Search in the News
BVGH published an article, *“WIPO Re:Search: Accelerating Anthelmintic Development Through Cross-sector Partnerships”*, in the *International Journal for Parasitology: Drugs and Drug Resistance*. This article features collaborations between Swiss TPH and the Eskitis Institute; the University of Buea and the University of British Columbia; and McGill University, AstraZeneca, and the Eskitis Institute. Three of the WIPO Re:Search capacity-building sabbaticals funded by the Australian government are also highlighted.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dec. 2-4</td>
<td>Joint International Tropical Medicine Meeting (JITMM 2014)</td>
<td>Bangkok, Thailand</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 9, 2015</td>
<td>7th Annual Center for Emerging &amp; Neglected Diseases (CEND) Symposium</td>
<td>Berkeley, CA</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 22-27, 2015</td>
<td>Keystone Symposium: Host Response in Tuberculosis</td>
<td>Santa Fe, NM</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Are you attending a global health event?*
Do you have a Research Request to highlight in the Snapshot?

We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members

*known as EMD in the US and Canada
**known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.

Forward this email

This email was sent to jdent@bvgh.org by jdent@bvgh.org | Update Profile/Email Address | Rapid removal with SafeUnsubscribe™ | Privacy Policy.

BIO Ventures for Global Health | 401 Terry Avenue North | Seattle | WA | 98109
December 2014

A Note from Jennifer

Dear WIPO Re:Search Members and Friends,

As 2014 draws to a close, I would like to thank our WIPO Re:Search Members for their commitment to neglected disease R&D and to the partnerships they have established through WIPO Re:Search.

We have over 80 collaborations in place, including several that are advancing to new stages of development. BVGH will not only be establishing new collaborations between Members in 2015, but will be investing its time in identifying additional partners that can further support the currently advancing collaborations.

Our team has identified several meetings and events that provide an ideal platform to present WIPO Re:Search to potential new Members, engage new researchers from current Members, and reconnect with scientists actively involved in WIPO Re:Search partnerships.

The BVGH team is looking forward to 2015 and the potential it holds for advancing current agreements and establishing promising new ones. With the recent addition of Merck KGaA, our Members will have access to additional industry compounds, data, and expertise to support their programs. The year ahead is shaping up to be an exciting and impactful year - thanks to the work and dedication of our Members.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
Special Announcement

WIPO has launched the renovated WIPO Re:Search website. Please click here to check it out.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

Cornerstones of Collaboration

Francis Gurry, Director General, WIPO, hosted a lunch in Geneva to welcome our newest pharmaceutical company Member, Merck KGaA, to the Consortium. Stefan Oschmann, CEO Pharma, Merck KGaA, was the guest of honor and spoke of the company's commitment to supporting WIPO Re:Search collaborations. The lunch was attended by WIPO Re:Search members, Bernard Pécoul, Executive Director, DNDi, Frédérique Santerre, Global Head, Access to Health, Merck KGaA, Eduardo Pisani, Director General, International Federation of Pharmaceutical Manufacturers & Associations, Tom Bombelles, Head, Global Health, WIPO, and Jennifer Dent, President, BVGH.
Partnership Hub Central

For two months this autumn, Benjamin Pinsky, Assistant Professor of Pathology and Medicine, and Jesse Waggoner, Instructor of Medicine, at the Stanford University School of Medicine, hosted Chika Celen Okangba, a doctoral student from the University of Lagos. Roopa Ramamoorthi met with Chika before her return to Nigeria. The two discussed the collaboration and Chika's experience at Stanford developing a PCR-based diagnostic customized to pathogens found predominantly in Lagos.

From left to right: Malaya Kumar Sahoo (Stanford University), Chika Celen Okangba (University of Lagos), Roopa Ramamoorthi (BVGH), and Alisha Hadley (Stanford University)

Ujwal Sheth presented WIPO Re:Search at the 2014 Joint International Tropical Medicine Meeting (JITMM) in Bangkok, Thailand. The meeting's theme focused on "3D perspectives on Tropical Medicine: Drivers, Diversity and Determination". During the conference, Ujwal spoke with scientists from the Walter and Eliza Hall Institute of Medical Research (WEHI), Mahidol
Highlighted Contributions

Featured this month is a contribution submitted by the University of South Florida to the WIPO Re:Search Database.

Access to Parasite Repository (ID: 2982)
The Donald Price Center for Parasite Repository and Education is directed by Prof. Ricardo Izurieta. The Center provides access to special educational materials on parasites including fecal specimens positive for a variety of parasites and whole parasite specimens. The Center also has microscope slides including (i) wet preparations from preserved specimens (ii) stained fecal smears (iii) stained blood films (iv) stained tissue sections showing pathology and (v) whole-mounts of parasites or stages of parasites.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.

WIPO Re:Search in the News

Merck KGaA's nascent membership in WIPO Re:Search was highlighted in an article in the Pharmaceutical Journal. Click here to read the story.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan. 9</td>
<td>7th Annual Center for Emerging &amp; Neglected Diseases (CEND) Symposium</td>
<td>Berkeley, CA</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 15-20</td>
<td>International Conference on Infectious and Tropical Diseases</td>
<td>Phnom Penh, Cambodia</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 22-27</td>
<td>Keystone Symposium: Host Response in Tuberculosis</td>
<td>Santa Fe, NM</td>
<td>Website</td>
</tr>
</tbody>
</table>

Are you attending a global health event? Do you have a Research Request to highlight in the Snapshot? We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members